Nintedanib Eg

Nintedanib, the active ingredient in Nintedanib Eg, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Nintedanib acts on multiple receptor tyrosine kinases involved in fibrotic and oncologic pathways, providing disease‑modifying benefits in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory status. - Non‑small cell lung cancer: used in combination regimens to inhibit tumor angiogenesis and growth.

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: frequent, may be mild to moderate. - Nausea: often transient. - Vomiting: occasional. - Decreased appetite: may affect nutritional intake. - Abdominal pain: mild to moderate. - Elevated liver enzymes (ALT/AST): usually reversible.

Serious or Rare Side Effects: - Hepatic failure: requires immediate medical attention. - Arterial thromboembolism: risk of stroke or myocardial infarction. - Severe bleeding: especially when combined with anticoagulants. - Gastrointestinal perforation: rare but life‑threatening. - Severe hypertension: may need antihypertensive therapy. - Serious infections: monitor for signs of pneumonia or sepsis.

Before initiating therapy, clinicians should assess baseline organ function and consider patient‑specific risk factors. - Liver function monitoring: check ALT/AST before start and periodically during treatment. - Cardiovascular risk: evaluate for history of arterial thromboembolism or uncontrolled hypertension. - Bleeding risk: avoid concomitant use with strong anticoagulants unless benefits outweigh risks. - Pregnancy and lactation: safety unknown; avoid use in pregnant or breastfeeding women. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib may interact with several drug classes, altering its exposure or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nintedanib plasma levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase risk of serious bleeding. - P‑glycoprotein inhibitors (e.g., verapamil): can elevate drug concentrations.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: monitor electrolytes and renal function when combined.